RNA microarray market set to grow to $2.52 billion by 2030

The global RNA microarray market rose to an estimated $1.77 billion in 2026 and is projected to reach $2.52 billion by 2030, driven by genomics research, personalized medicine and cancer diagnostics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - RNA microarrays are becoming more important in gene expression research, clinical diagnostics and drug development. - The market’s growth signals rising demand for tools that can help identify disease biomarkers, support personalized medicine and speed up transcriptomic analysis. - The market is moving from $1.61 billion in 2025 to an estimated $1.77 billion in 2026, and toward $2.52 billion by 2030.

What happened: - The Business Research Company released an outlook for the RNA microarray market on Sept. 22, 2026. - The report says the market grew at a 9.7% CAGR from 2025 to 2026. - The market is forecast to grow at a 9.3% CAGR from 2026 to 2030. - North America held the largest regional share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - RNA microarray technology measures the expression levels of thousands of RNA transcripts from a single biological sample. - The method uses labeled RNA or complementary DNA hybridized to probes on a solid surface. - The technology helps researchers detect, quantify and compare gene expression patterns. - Growth is being supported by advances in genomic research, gene expression studies and DNA and RNA hybridization-based microarray platforms. - Clinical diagnostics use of gene expression profiling is adding to demand. - Pharmaceutical research using transcriptomic data and high-throughput molecular biology techniques is also expanding the market. - The report says AI tools for gene expression analysis will be a key growth driver. - Other future drivers include personalized medicine, biomarker discovery, multi-omics research, systems biology, automated high-throughput platforms and cloud-enabled genomic analytics and storage. - Emerging trends include AI-powered gene expression platforms, cloud-based bioinformatics pipelines, high-density microarray chips and more automation in scanning and hybridization systems. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company also highlighted market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables in its 2026 reports.

Between the lines: - Personalized medicine is a major demand driver because RNA microarrays can profile thousands of genes at once and help match treatments to molecular signatures. - Cancer prevalence is another major tailwind because the technology supports tumor biomarker discovery, disease-mechanism studies and treatment-response analysis. - The American Cancer Society reported 1,958,310 new cancer cases in 2023, up from 1,918,030 in 2022. - Government funding is helping move genomic research and high-throughput gene-expression tools forward. - The Earlham Institute received $39.7 million in May 2023 from the Biotechnology and Biological Sciences Research Council for a five-year program. - The report points to a broader shift toward automation and data-heavy analysis, which favors platforms that combine lab workflows with software and cloud infrastructure.

What's next: - The market is expected to keep expanding through 2030 as AI, automation and cloud-based analysis become more common in genomic workflows. - Growth opportunities are likely to concentrate in personalized medicine, oncology research and multi-omics applications. - Asia-Pacific may narrow the gap with North America if current growth trends continue.

The bottom line: - RNA microarrays are moving from a niche research tool toward a broader role in diagnostics and precision medicine, and the market outlook remains firmly positive.